查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003093

毒理學和藥物篩檢市場：按測試類型、產品類型、檢體類型、藥物類別、應用和最終用戶分類－2026-2032年全球市場預測

Toxicology Drug Screening Market by Test Type, Product Type, Sample Type, Drug Class, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，毒理學藥物篩檢市場價值將達到 342.3 億美元，到 2026 年將成長至 383 億美元，到 2032 年將達到 861.5 億美元，複合年成長率為 14.09%。

主要市場統計數據
基準年 2025 342.3億美元
預計年份：2026年 383億美元
預測年份：2032年 861.5億美元
複合年成長率 (%) 14.09%

本執行概述概述了技術創新、監管壓力和臨床需求如何重塑毒理學藥物篩檢的策略和投資決策。

由於技術、法規和臨床需求等多種因素的相互作用，毒理學中的藥物篩檢正處於轉折點。分析儀器和分子診斷技術的進步擴大了可檢測分析物的範圍，並提高了靈敏度。同時，臨床途徑和法醫學要求的演變也要求更快、更準確地獲得結果。此外，實驗室也面臨越來越大的壓力，需要提高處理能力、縮短結果時間，並確保符合不同司法管轄區的法規要求。

技術進步、驗證要求以及分散式檢查模型的整合如何重新定義藥物篩檢中的檢查室操作和服務交付？

毒理學藥物篩檢領域正經歷一場變革，其驅動力包括高解析度分析技術的整合、分子檢測方法的普及以及對照護現場便利性的日益重視。層析法-質譜聯用技術正從小眾的確認工具發展成為可靠檢測流程的基礎，在複雜的藥物基質和多重用藥的情況下展現出更高的特異性。同時，免疫檢測和側向層析技術也不斷發展，提供日益強大的篩檢能力，與確認平台形成互補。

評估 2025 年關稅變化對毒理學檢測的採購、供應鏈韌性和服務交付的營運影響。

2025年推出的關稅和貿易政策對毒理學檢查室的採購、設備維護和耗材供應鏈產生了累積影響。進口設備和零件關稅的提高可能會增加層析法系統、質譜儀和PCR設備的購置成本，迫使檢查室重新考慮其採購計劃，並優先考慮模組化升級而非整體平台更換。除了資本設備外，試劑、檢測試劑盒和專用耗材的關稅也會導致單位成本波動，進而影響檢測項目的組成以及內部和外包確認檢測服務的經濟效益。

將測試方式、產品系列、檢體基質、藥物標靶、應用和最終用戶趨勢連結起來的多層次細分觀點，以建立可操作的檢查室策略。

詳細的細分觀點闡明了技術、臨床和商業性優先事項在檢測類型、產品系列、檢體基質、藥物標靶、應用和最終用戶方面的交匯點。檢測類型包括層析法和質譜平台，這些平台又細分為高可靠性確證氣相層析層析法聯用和液相層析法串聯式質譜質譜聯用，以及免疫檢測篩檢篩檢和分子診斷，涵蓋從下一代定序到基於PCR的檢測方法。快速檢測方案是上述檢測的補充，並支援分散式篩檢點的運作。

區域趨勢和監管差異影響全球毒性測試市場的技術採用、供應鏈策略和服務交付模式。

區域趨勢影響著技術採納、監管合規和服務交付模式，並成為策略規劃和供應商合作的關鍵要素。在美洲，醫療保健系統和法醫學網路傾向於快速採用高解析度層析法和質譜技術，這得益於成熟的報銷管道支援集中式檢查室模式、大批量臨床檢測和確證性檢測。監管要求強調經驗證的檢驗調查方法和儲存管理通訊協定，這些是刑事鑑定和職場檢測的基礎；同時，分散式醫療保健的趨勢也推動了對快速現場篩檢檢測的需求成長。

競爭優勢源自於毒理學測試中的整合儀器、檢驗的檢測組合、服務夥伴關係以及供應鏈透明度。

藥物篩檢領域的競爭格局呈現出全球儀器製造商、專業檢測方法開發公司以及提供確證檢測和諮詢服務的服務供應商並存的局面。領先的儀器供應商利用整合平台，將強大的層析法系統和高靈敏度質譜儀相結合，並配備用於數據收集、解讀和檢查室資訊管理的軟體生態系統。這些供應商憑藉強大的處理能力、完善的支援網路和方法庫脫穎而出，從而縮短複雜檢測項目的檢驗週期。

為領導者提供的實用策略措施，以增強毒理學服務的韌性，使測試管道多樣化，並最佳化採購和人力資源能力。

產業領導者應採取平衡策略，強調韌性、敏捷性和臨床有效性。首先，應優先考慮在篩檢和確證檢測模式方面實現產品組合多元化，以應對供應鏈中斷，並使檢查室能夠選擇滿足其臨床和法醫學需求的檢測方法。同時投資於使用免疫檢測的快速篩檢和使用層析法-質譜聯用技術的確證檢測能力，將確保在關鍵案例中進行正確的分類，並維護結果的完整性。

為了提供實際的見解，我們採用了嚴謹的多方面研究途徑，結合了專家訪談、監管審查、供應鏈映射和技術性能評估。

本分析所依據的研究採用了多模態方法，以確保其穩健性和對所有檢查室環境的適用性。主要資料收集包括對實驗室經理、採購經理和服務供應商進行結構化訪談，以了解實際營運、採購限制和驗證實務。除這些定性見解外，還對監管指南、認證標準和技術驗證文獻進行了系統性回顧，以支持關於測試方法選擇、報告和合規性的討論。

策略整合強調技術整合、供應鏈韌性和人才培養，以確保可靠且可擴展的毒理學服務。

總之，毒理學藥物篩檢正朝著更一體化和技術主導的方向發展，這需要對儀器和檢測方法的選擇、供應鏈管理以及人力資源能力進行策略性協調。能夠成功應對這項變革的檢查室和服務供應商，能夠恰當地平衡對可靠確認平台的投資與快速分子水平篩檢工具的實際應用，以滿足多樣化的臨床和法醫學需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：毒理學和藥物篩檢市場：按測試類型分類

  • 層析法和質譜
    • 氣相層析法聯用
    • 液相層析法-串聯式質譜質譜法
  • 免疫檢測
  • 分子診斷
    • 下一代定序
    • 基於PCR的檢測
  • 快速檢測

第9章：毒理學和藥物篩檢市場：按產品類型分類

  • 層析法系統
  • 驗證服務
  • 諮詢服務
  • 酵素免疫分析法（ELISA）試劑盒
  • 側向流動免疫檢測試劑盒
  • 質譜儀
  • PCR裝置
  • 篩檢服務

第10章：毒理學和藥物篩檢市場：按檢體類型分類

  • 血
    • 電漿
    • 全血
  • 頭髮
  • 口腔液
  • 唾液
  • 尿

第11章：毒理學藥物篩檢市場：依藥物類別分類

  • 安非他命
  • 苯二氮平類藥物
  • 大麻
  • 古柯鹼
  • 鴉片類藥物

第12章：毒理學和藥物篩檢市場：按應用領域分類

  • 臨床診斷
  • 刑事鑑定
  • 疼痛管理
  • 體育反興奮劑
  • 職場檢查

第13章：毒理學和藥物篩檢市場：按最終用戶分類

  • 政府和軍事實驗室
  • 家庭測試
  • 醫院和診所
  • 私人考試機構
  • 研究機構

第14章：毒理學和藥物篩檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：毒理學和藥物篩檢市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：毒理學和藥物篩檢市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國毒理學和藥物篩檢市場

第18章：中國毒理學和藥物篩檢市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alere Inc.
  • ARK Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Mindray Bio-Medical Electronics Co., Ltd.
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-AD517FAA7D9A

The Toxicology Drug Screening Market was valued at USD 34.23 billion in 2025 and is projected to grow to USD 38.30 billion in 2026, with a CAGR of 14.09%, reaching USD 86.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.23 billion
Estimated Year [2026] USD 38.30 billion
Forecast Year [2032] USD 86.15 billion
CAGR (%) 14.09%

An executive overview that frames technological innovation, regulatory pressures, and clinical demand reshaping toxicology drug screening strategy and investment choices

The toxicology drug screening landscape stands at an inflection point driven by converging forces in technology, regulation, and clinical demand. Advances in analytical instrumentation and molecular diagnostics are expanding the scope of detectable analytes and improving sensitivity, while evolving clinical pathways and forensic requirements are demanding faster, more accurate results. At the same time, laboratories face intensified pressure to enhance throughput, reduce time-to-result, and maintain compliance across diverse jurisdictions.

This executive summary synthesizes key developments shaping test adoption and provider strategies. It speaks to clinical laboratory directors, procurement teams, forensic leaders, and manufacturers who must balance capital investments in chromatography and mass spectrometry platforms with scalable screening solutions such as immunoassays and rapid tests. The introduction frames the discussion by articulating how methodological choice, sample handling protocols, and downstream confirmatory workflows combine to determine operational performance and stakeholder confidence.

Through this lens, readers will find a clear orientation to recent innovations, regulatory inflections, and competitive dynamics that influence decision-making. The goal is to provide a concise yet comprehensive entry point that prepares leaders to interpret deeper segmentation analysis and regional intelligence supplied in subsequent sections.

How converging technological advances, validation requirements, and decentralized testing models are redefining laboratory operations and service delivery in toxicology screening

The landscape of toxicology drug screening is undergoing transformative shifts driven by the integration of high-resolution analytical techniques, the mainstreaming of molecular assays, and a renewed emphasis on point-of-care accessibility. Chromatography coupled with mass spectrometry has transitioned from a niche confirmation tool to a cornerstone of high-confidence testing workflows, yielding greater specificity for complex drug matrices and polypharmacy cases. Simultaneously, immunoassays and lateral flow technologies continue to evolve, offering increasingly robust screening capability that complements confirmatory platforms.

Next-generation sequencing and PCR-based modalities are extending toxicology beyond traditional metabolites to include genetic and pathogen interactions that influence drug metabolism and interpretation. This molecular overlay supports personalized approaches to pain management and forensic toxicology, while raising the bar for laboratory informatics and result interpretation. Rapid testing modalities are also becoming more clinically acceptable as sensitivity and specificity improve, enabling decentralized testing in workplace, emergency, and community settings.

Operationally, these technological shifts drive changes in capital allocation, workforce skill requirements, and quality assurance protocols. Laboratories must invest in staff training on mass spectrometric data interpretation and molecular assay validation. Meanwhile, cross-disciplinary collaboration between clinical chemists, molecular scientists, and IT specialists becomes essential to realize the full benefit of integrated testing strategies. Regulators and accreditation bodies are responding with updated guidance that emphasizes method validation, traceability, and standardized reporting, which in turn influences procurement cycles and vendor selection.

Assessing the operational consequences of 2025 tariff shifts on procurement, supply chain resilience, and service delivery in toxicology testing

Tariffs and trade policy introduced during 2025 have produced cumulative impacts that extend across procurement, instrument servicing, and consumables supply chains for toxicology laboratories. Increased duties on imported instrumentation and components can raise acquisition costs for chromatography systems, mass spectrometers, and PCR instruments, prompting laboratories to reassess purchasing timelines and prioritize modular upgrades over full platform replacements. Beyond capital equipment, tariffs on reagents, assay kits, and specialized consumables create variability in unit costs that influence test mix decisions and the economics of in-house versus outsourced confirmation services.

Suppliers who rely on globalized manufacturing networks face pressure to reconfigure supply chains, which may introduce lead time volatility and increased inventory holding as a hedge against further trade disruptions. Such dynamics encourage buyers to diversify vendor relationships and to negotiate long-term supply agreements that include contingency clauses for tariff-related price adjustments. For service-oriented offerings such as confirmation services and consultation services, tariffs exert an indirect influence by altering the cost base of laboratory operations and potentially shifting demand between domestic and international providers.

In response, laboratory managers and procurement teams should evaluate total cost of ownership more holistically, accounting for maintenance, calibration, and parts availability against initial purchase price. Strategic sourcing decisions will increasingly weigh the benefits of localized manufacturing and regional support networks that can mitigate tariff exposure, while also prioritizing vendors with transparent supply chain mapping and flexible contractual terms.

A layered segmentation perspective that connects test modalities, product portfolios, sample matrices, drug targets, applications, and end-user dynamics to actionable laboratory strategy

A granular view of segmentation clarifies where technological, clinical, and commercial priorities intersect across test types, product portfolios, sample matrices, drug targets, applications, and end users. Test types include chromatography and mass spectrometry platforms that are detailed into gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for high-confidence confirmatory testing, alongside immunoassay-based screening formats and molecular diagnostics that span next-generation sequencing and PCR-based testing; rapid testing options complete the spectrum and support decentralized screening points.

Product type segmentation ranges from chromatography systems and mass spectrometers to enzyme-linked immunosorbent assay kits, lateral flow immunoassay kits, PCR instruments, and a suite of services including screening services, confirmation services, and consultation services that guide method selection and result interpretation. Sample type considerations reflect differing pre-analytical workflows and detection windows, encompassing blood with plasma and whole blood distinctions, hair, oral fluid, saliva, and urine; each matrix presents unique extraction, stability, and interpretive challenges that inform test choice.

Drug class segmentation focuses on clinically and forensically relevant analytes such as amphetamines, benzodiazepines, cannabis, cocaine, and opiates. Application segments include clinical diagnostics, forensic testing, pain management, sports anti-doping, and workplace testing, each with distinct regulatory, turnaround time, and reporting requirements. End users span government and military laboratories, home care testing scenarios, hospitals and clinics, independent laboratories, and research institutes, creating a diverse demand profile where procurement cycles, required accreditation, and throughput expectations vary considerably. Together, these segmentation layers illuminate where investment in instrumentation, assay development, and service delivery will yield the greatest operational and clinical return.

Regional dynamics and regulatory diversity that influence technology adoption, supply chain strategy, and service delivery models across global toxicology testing markets

Regional dynamics shape technology adoption, regulatory compliance, and service delivery models in ways that are important for strategic planning and vendor engagement. In the Americas, healthcare systems and forensic networks tend to favor rapid adoption of high-resolution chromatography and mass spectrometry driven by centralized laboratory models, high-volume clinical testing, and established reimbursement pathways that support confirmatory testing. Regulatory expectations emphasize validated methodologies and chain-of-custody protocols that underpin forensic and workplace testing, while decentralized care trends are expanding demand for rapid and point-of-care screening options.

Europe, Middle East & Africa exhibit substantial heterogeneity in capability and regulatory frameworks. Established markets emphasize harmonized standards and accreditation, driving uptake of advanced analytical platforms and a growing interest in molecular diagnostics for complex cases. Emerging markets within the region focus on scalable screening solutions, training, and infrastructural investments to bridge gaps in laboratory capacity. Cross-border regulatory mechanisms and regional reference laboratories play a critical role in standardizing practice and enabling access to confirmatory services.

Asia-Pacific combines rapid technological adoption with large and diverse patient populations, creating high demand for both high-throughput laboratory platforms and cost-effective rapid tests. Investments in domestic manufacturing and regional supply chains are accelerating, supported by public health initiatives that integrate toxicology screening into clinical and forensic workflows. Across all regions, the interplay between local regulatory requirements, procurement practices, and supply chain resilience informs how laboratory leaders prioritize capital projects and vendor partnerships.

Competitive differentiation driven by integrated instrumentation, validated assay portfolios, service partnerships, and supply chain transparency in toxicology testing

Competitive positioning in toxicology drug screening reflects a mix of global instrument manufacturers, specialized assay developers, and service providers offering confirmation and consultation services. Key instrument vendors leverage integrated platforms that combine robust chromatography systems with high-sensitivity mass spectrometers, accompanied by software ecosystems for data acquisition, interpretation, and laboratory information management. These vendors differentiate on throughput capability, support networks, and method libraries that reduce validation timelines for complex panels.

Assay manufacturers and kit suppliers compete on sensitivity, specificity, lot-to-lot consistency, and ease of use, particularly for immunoassays and lateral flow tests that serve decentralized settings. PCR and sequencing instrument providers focus on automation, sample throughput, and bioinformatics support that enable molecular toxicology applications, while independent laboratories and service providers emphasize accreditation, chain-of-custody integrity, and rapid turnaround for confirmatory testing.

Partnerships between instrument manufacturers and service laboratories increasingly shape go-to-market approaches, allowing vendors to offer bundled solutions that combine hardware, consumables, and validation services. Companies that invest in training, remote diagnostics, and predictive maintenance for installed instrumentation gain competitive advantage by reducing downtime and total cost of ownership for end users. Finally, firms that transparently manage supply chains and demonstrate agility in tariff and trade environments position themselves as reliable partners for large-scale deployments and time-sensitive forensic contracts.

Practical strategic moves for leaders to bolster resilience, diversify testing pathways, and optimize procurement and workforce capabilities in toxicology services

Industry leaders should pursue a balanced approach that emphasizes resilience, agility, and clinical relevance. First, prioritize portfolio diversification across screening and confirmatory modalities so laboratories can match test selection to clinical and forensic needs while hedging against supply chain disruptions. Investing in both immunoassay-based rapid screens and chromatography-mass spectrometry confirmation capability ensures appropriate triage and maintains result integrity for high-stakes cases.

Second, strengthen supplier relationships with a focus on long-term contracts, local support capabilities, and clear escalation pathways for parts and servicing. Negotiating terms that address tariff volatility and lead-time contingencies reduces procurement risk and stabilizes operational budgets. Third, commit to workforce development by allocating resources to upskill analytical chemists and molecular technologists in mass spectrometric interpretation, molecular assay validation, and laboratory informatics. Cross-training enhances flexibility and supports hybrid testing models.

Fourth, adopt data governance and interoperability standards that facilitate result comparability across instruments, laboratories, and jurisdictions, including robust quality control programs and audit-ready documentation. Finally, incorporate scenario planning into capital investment decisions to account for regulatory shifts, reimbursement changes, and geopolitical trade dynamics, enabling faster pivots when external conditions change.

A rigorous multi-method research approach combining expert interviews, regulatory review, supply chain mapping, and technical performance evaluation to underpin practical insights

The research underpinning this analysis combined a multi-modal approach to ensure robustness and applicability across laboratory settings. Primary data collection included structured interviews with laboratory directors, procurement managers, and service providers to capture operational realities, procurement constraints, and validation practices. These qualitative insights were complemented by a systematic review of regulatory guidance, accreditation standards, and technical validation literature to ground discussions of method selection, reporting, and compliance.

Supply chain analysis examined vendor manufacturing footprints, logistics pathways, and tariff-sensitivity to assess procurement risk and lead-time volatility. Technical evaluation of instrumentation and assays was informed by performance specifications, peer-reviewed validation studies, and vendor method summaries to compare sensitivity, specificity, and throughput characteristics across platforms. The methodology also incorporated scenario-based analysis to explore the implications of trade policy changes and regional procurement variations on laboratory operations.

Triangulation across these sources ensured that conclusions reflect both field practice and documented performance, while expert review cycles validated interpretive frameworks and recommendations. Ethical considerations and data privacy protocols guided interview conduct and the handling of proprietary information throughout the research process.

A strategic synthesis emphasizing technology integration, supply chain resilience, and workforce development to ensure reliable and scalable toxicology services

In conclusion, toxicology drug screening is evolving into a more integrated, technology-driven field that requires strategic alignment across instrumentation, assay selection, supply chain management, and workforce capabilities. Laboratories and service providers that successfully navigate this evolution will be those that balance investment in high-confidence confirmatory platforms with pragmatic adoption of rapid and molecular screening tools to meet diverse clinical and forensic needs.

Operational resilience, enabled by diversified procurement strategies and supplier partnerships, will be critical in an environment shaped by tariff fluctuations and regional supply dynamics. Equally important is the development of internal expertise and interoperable data systems that allow organizations to extract maximal clinical value from test results while maintaining compliance with evolving regulatory expectations. By focusing on these areas-technology integration, supply chain agility, and human capital-decision-makers can translate analytical advancements into reliable, scalable services that meet the rising demand for timely and accurate toxicology testing.

This executive summary serves as a strategic roadmap for stakeholders aiming to align short-term operational decisions with longer-term capability development in toxicology screening.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Toxicology Drug Screening Market, by Test Type

  • 8.1. Chromatography And Mass Spectrometry
    • 8.1.1. Gas Chromatography-Mass Spectrometry
    • 8.1.2. Liquid Chromatography-Tandem Mass Spectrometry
  • 8.2. Immunoassay
  • 8.3. Molecular Diagnostics
    • 8.3.1. Next-Generation Sequencing
    • 8.3.2. PCR-Based Testing
  • 8.4. Rapid Testing

9. Toxicology Drug Screening Market, by Product Type

  • 9.1. Chromatography Systems
  • 9.2. Confirmation Services
  • 9.3. Consultation Services
  • 9.4. Enzyme-Linked Immunosorbent Assay Kits
  • 9.5. Lateral Flow Immunoassay Kits
  • 9.6. Mass Spectrometers
  • 9.7. PCR Instruments
  • 9.8. Screening Services

10. Toxicology Drug Screening Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Whole Blood
  • 10.2. Hair
  • 10.3. Oral Fluid
  • 10.4. Saliva
  • 10.5. Urine

11. Toxicology Drug Screening Market, by Drug Class

  • 11.1. Amphetamines
  • 11.2. Benzodiazepines
  • 11.3. Cannabis
  • 11.4. Cocaine
  • 11.5. Opiates

12. Toxicology Drug Screening Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Forensic Testing
  • 12.3. Pain Management
  • 12.4. Sports Anti-Doping
  • 12.5. Workplace Testing

13. Toxicology Drug Screening Market, by End User

  • 13.1. Government And Military Laboratories
  • 13.2. Home Care Testing
  • 13.3. Hospitals And Clinics
  • 13.4. Independent Laboratories
  • 13.5. Research Institutes

14. Toxicology Drug Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Toxicology Drug Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Toxicology Drug Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Toxicology Drug Screening Market

18. China Toxicology Drug Screening Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Alere Inc.
  • 19.8. ARK Diagnostics, Inc.
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories, Inc.
  • 19.11. Charles River Laboratories International, Inc.
  • 19.12. Danaher Corporation
  • 19.13. Eurofins Scientific SE
  • 19.14. F. Hoffmann-La Roche Ltd
  • 19.15. Laboratory Corporation of America Holdings
  • 19.16. Merck KGaA
  • 19.17. Mindray Bio-Medical Electronics Co., Ltd.
  • 19.18. OraSure Technologies, Inc.
  • 19.19. Ortho Clinical Diagnostics
  • 19.20. PerkinElmer, Inc.
  • 19.21. Quest Diagnostics Incorporated
  • 19.22. Shimadzu Corporation
  • 19.23. Siemens Healthineers AG
  • 19.24. Sysmex Corporation
  • 19.25. Thermo Fisher Scientific Inc.
  • 19.26. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 224. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 254. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 264. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)